This Guidelines summary covers an antimicrobial prescribing strategy for secondary bacterial infection of eczema and covers infection of other common skin conditions
The purpose of this Guidelines summary is to maximise the safety of children and adults who have dermatological conditions treated with drugs affecting the immune response during the COVID-19 pandemic
This NICE guideline summary sets out an antimicrobial prescribing strategy for human and animal bites (excluding insect bites) in adults, young people and children aged 72 hours and over
This summary has been developed for use by community pharmacists under our Guidelines for Pharmacy title and therefore only covers the information relevant to this setting. Areas covered include: treatment and management, advantages and disadvantages of treatment options, information and advice for those with the condition. Please refer to the full guideline for the complete set of recommendations.
These videos have been funded by Galderma UK Ltd and developed in conjunction with Guidelines. The content on this page is intended for UK healthcare professionals only.
View Epiduo 0.1%/2.5% (adapalene and benzoyl peroxide) gel prescribing information
View Epiduo 0.3%/2.5% (adapalene and benzoyl peroxide) gel prescribing information
UKI-NBD-2100060 | January 2022
The production of this Guidelines card has been commissioned by Almirall Ltd.
View prescribing and adverse event reporting information
IE-KLI-2100016 December 2021
Information intended for UK healthcare professionals only. This promotional supplement has been commissioned and funded by Galderma and developed in partnership with Guidelines.
View Epiduo Gel 0.1% (0.1% adapalene & 2.5% benzoyl peroxide) prescribing information and adverse event reporting information.
View Epiduo Gel 0.3%/2.5 % (0.3% adapalene & 2.5% benzoyl peroxide) prescribing information and adverse event reporting information.
Date of preparation: October 2021
This prescribing summary card was developed from content provided by Galderma UK Ltd. Information intended for UK healthcare professionals only.
View Soolantra® (ivermectin) 10 mg/g cream prescribing and adverse event reporting information.
UKI-SOC-2100031 September 2021
This concise consultation card was developed by Guidelines for Pharmacy in partnership with Reckitt.
Essential information and adverse reporting details are included.
RB-M-39417 July 2021